Loading...
Loading...
CDT| Name | Value |
|---|---|
| Revenues | 604.3M |
| Cost of Revenue | 377.5M |
| Gross Profit | 226.8M |
| Operating Expense | 3.1M |
| Operating I/L | -3.1M |
| Other Income/Expense | -2.2M |
| Interest Income | 0.0M |
| Pretax | -5.4M |
| Income Tax Expense | -11.1M |
| Net Income/Loss | -5.4M |
Conduit Pharmaceuticals Inc. is a clinical stage specialty biopharmaceutical company focused on addressing unmet medical needs in autoimmune disease and idiopathic male infertility. The company's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. By developing innovative treatments for these conditions, Conduit Pharmaceuticals Inc. aims to generate revenue through the commercialization of its pharmaceutical products and the licensing of its intellectual property to other pharmaceutical companies.
